Fig. 5
SD administration prevents loss of motor neurons and modulates LSD1 activity in the lumbar spinal cord of G93A mice. A SD administration prevented loss of ChAT-positive motor neurons (red) while reducing the immunoreactivity of GFAP (green) in the ventral horn of G93A mice. Scale bars (white): 50 μm. B SD administration improved the volume (µm3) of the motor neuron cell body. The number of cell counting: 12 cells/group. C SD significantly decreased the immunoreactivity of GFAP in G93A mice compared to WT mice. The intensity of GFAP immunoreactivity (in six foci of the ventral gray matter) was analyzed by NIH ImageJ program. D LSD1 activity was significantly elevated in mSOD1 ALS (G93A) mice (n = 5) in comparison to WT mice (n = 5). SD administration decreased the LSD1 activity in mSOD1 ALS (G93A) mice (n = 5) but not in WT mice (n = 5) at 120 days of age. SD and saline were separately administered (5 mg/kg, I.P. injection) to groups of 6 wildtype and G93A mice from 30 to 120 days of age. Significantly different at *p < 0.05 and **p < 0.01